Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration at Twenty-four Months: the Pan-American Collaborative Retina Study

Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration at Twenty-four Months: the Pan-American Collaborative Retina Study

Author Fernando Arevalo, J. Google Scholar
Sanchez, Juan G. Google Scholar
Wu, Lihteh Google Scholar
Berrocal, Maria H. Google Scholar
Alezzandrini, Arturo A. Google Scholar
Restrepo, Natalia Google Scholar
Maia, Mauricio Autor UNIFESP Google Scholar
Farah, Michel E. Autor UNIFESP Google Scholar
Brito, Miguel Google Scholar
Diaz-Llopis, Manuel Google Scholar
Rodriguez, Francisco J. Google Scholar
Reategui, Guillermo Google Scholar
Iturralde-Iraola, Juan Google Scholar
Udaondo-Mirete, Patricia Google Scholar
Pan-Amer Collaborative Retina Stud Google Scholar
Institution Clin Oftalmolog
Inst Nacl Invest Oftalmol
Inst Cirugia Ocular
Univ Puerto Rico
Univ Buenos Aires
Universidade Federal de São Paulo (UNIFESP)
Inst Docente Especialidades Oftalmol
Gen Univ Valencia
Univ Rosario
Inst Nacl Oftalmol
Abstract Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (IVB) (Avastin; Genentech Inc., San Francisco, CA) (1.25 or 2.5 mg) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).Design: Retrospective, multicenter, interventional, comparative case series.Participants: We reviewed the clinical records of 180 consecutive patients (207 eyes) with subfoveal CNV secondary to AMD at 9 centers from 8 countries.Methods: Patients were treated with at least 1 injection of IVB 1.25 mg (124 eyes [59.9%]) or 2.5 mg (83 eyes [40.1%]). Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and 1-, 3-, 6-, 12-, and 24-month visits.Main Outcome Measures: Changes in BCVA and OCT.Results: the mean age of our patients was 74.3 +/- 7.5 years. the mean number of IVB injections per eye was 5.1 (range, 1- 24 injections). in the 1.25 mg group, baseline BCVA improved from 20/235 (logarithm of the minimum angle of resolution [logMAR] 1.07) to 20/172 (logMAR 0.92) at 24 months (P<0.0001). Similar BCVA changes were observed in the 2.5 mg group. At baseline, the mean central macular thickness (CMT) by OCT in the 1.25 mg group was 308.4 +/- 127.52 mu m, which was reduced to 269.35 +/- 97.92 mu m, 262.1 +/- 94.81 mu m, 264.03 +/- 97.06 mu m, 245.91 +/- 89.52 mu m, and 249.27 +/- 89.14 mu m at 1, 3, 6, 12, and 24 months, respectively (P<0.0001). Similar changes were observed in the 2.5 mg group. in the 2.5 mg group, systemic complications included 2 new cases (2.6%) of arterial hypertension, 1 case (1.3%) of stroke, and 1 case (1.3%) of death.Conclusions: Primary IVB at a dose of 1.25 or 2.5 mg seems to provide stability or improvement in BCVA, OCT, and FA in subfoveal CNV secondary to AMD at 24 months. Our results show no significant difference regarding BCVA with IVB at doses of 1.25 or 2.5 mg.
Language English
Sponsor Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela
Date 2010-10-01
Published in Ophthalmology. New York: Elsevier B.V., v. 117, n. 10, p. 1974-U155, 2010.
ISSN 0161-6420 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 1974-U155
Origin http://dx.doi.org/10.1016/j.ophtha.2010.01.056
Access rights Closed access
Type Article
Web of Science ID WOS:000282370100017
URI http://repositorio.unifesp.br/handle/11600/32959

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account